SHANG.FOS.PHARM.GR.H YC 1

Research SHANG.FOS.PHARM.GR.H YC 1 (08HH) on Bullrun: market cap EUR 4.76B, P/E 11.1, dividend yield 2.8%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 4.76B; P/E is 11.1; dividend yield is 2.8%.

Peer valuation comparison

Latest P/E is 11.13x versus a Healthcare sector median of 24.46x (54.5% below).

Latest dividend yield is 2.79% versus a Healthcare sector median of 2.11% (32.2% above).

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-27EUR 4.76B11.12.8%0.05

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.05 EUR, yield 2.8%.

About SHANG.FOS.PHARM.GR.H YC 1

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others.

Related stock research

China stocks China Healthcare stocks A-Z stock index

Other Healthcare stocks

Jiangsu Hengrui Pharmaceuticals Co.,Ltd (0BO) HANSOH PHARMAC. HD-00001 (3KY) CONSUN PHARMAC.GR.HD -10 (C1P) China Shineway Pharmaceutical Group Limited (C1S) CanSino Biologics Inc (CJH) LIVZON PHARMAC. GRP H YC1 (LP6) Luye Pharma Group Ltd (LUP) SIMCERE PHARMAC. GRP LTD (S2P) Shandong Xinhua Pharmaceutical Company Limited (XIN) YIDU TECH INC. DL -00002 (0EL) China Resources Medical Holdings Company Limited (1515.HK) WUXI BIOLOGICS-00000083 (1FW2)

Frequently asked questions

What is SHANG.FOS.PHARM.GR.H YC 1's market cap?

SHANG.FOS.PHARM.GR.H YC 1's market capitalization is EUR 4.76B.

What is SHANG.FOS.PHARM.GR.H YC 1's P/E ratio?

SHANG.FOS.PHARM.GR.H YC 1's price-to-earnings (P/E) ratio is 11.1.

Does SHANG.FOS.PHARM.GR.H YC 1 pay a dividend?

SHANG.FOS.PHARM.GR.H YC 1 has a dividend yield of 2.8%.

What does SHANG.FOS.PHARM.GR.H YC 1 do?

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates.